A prospective survey on therapeutic inertia in psoriatic arthritis (OPTI'PsA).

"seven clinical cases illustrating common situations in clinical practice and reflecting the polymorphous nature of psa were designed by the scientific committee ( supplementary data s1 and s2 available at rheumatology online).; between january and march 2021 825 french rheumatologists were contacted via email by the research company aplusa and invited to complete an online questionnaire ( supplementary data s3 available at rheumatology online).; between 21 january and 4 march 2021 101 rheumatologists responded to the online questionnaire giving a response rate of 12% ( supplementary data s4 and s5 available at rheumatology online).; almost all surveyed rheumatologists declared themselves 'comfortable' with the management of psa (99% of total or overall agreement) ( supplementary data s6 available at rheumatology online).; also a significant proportion reported using an assessment score (das disease activity index for psoriatic arthritis [dapsa] minimal disease activity [mda]) on a daily basis (69% of total or overall agreement) ( supplementary data s7 available at rheumatology online).; we saw that 97% of respondents attended and/or followed communications presented during at least one international national or regional conference in the 2 years prior to the study ( supplementary data s8 available at rheumatology online).; nevertheless we feel that the relatively large size of our sample of respondents its representativeness in terms of types of practice and geographical distribution in our country ( supplementary data s5 available at rheumatology online) and its pragmatic approach by clinical vignettes [ ] allow us to draw certain conclusions."

"Disclosure statement : F.L.: Amgen, Biogen, Celgene, Fresenius Kabi, Janssen, Lilly, Mylan-Viatris, Nordic Pharma, Sandoz. E.D.: Amgen, Celgene, Lilly, Janssen, Abbvie, Arthrex. J.B.Q.: Amgen employee. A.F.: Abbvie, Amgen, BMS, Celgene, Chugai, Fresenius Kabi, UCB, Roche, Pfizer, Novartis, Lilly, Janssen. A.C.: Abbvie, Amgen, Biogen, BMS, Fresenius Kabi, Janssen, Lilly, Medac, MSD, Mylan-Viatris, Novartis, Pfizer, Roche, Sanofi, UCB. F.L., A.C., E.D., J.B.Q., A.F., J.S.: PI, co-PI, conference and expertise fees from Amgen. The 101 participating physicians received a participation fee from APLUSA, based on a contract validated by the Conseil National de l’Ordre des Médecins (CNOM)."

"Funding This study received institutional but non-interventional support from Amgen. Disclosure statement: F.L.: Amgen, Biogen, Celgene, Fresenius Kabi, Janssen, Lilly, Mylan-Viatris, Nordic Pharma, Sandoz. E.D.: Amgen, Celgene, Lilly, Janssen, Abbvie, Arthrex. J.B.Q.: Amgen employee. A.F.: Abbvie, Amgen, BMS, Celgene, Chugai, Fresenius Kabi, UCB, Roche, Pfizer, Novartis, Lilly, Janssen. A.C.: Abbvie, Amgen, Biogen, BMS, Fresenius Kabi, Janssen, Lilly, Medac, MSD, Mylan-Viatris, Novartis, Pfizer, Roche, Sanofi, UCB. F.L., A.C., E.D., J.B.Q., A.F., J.S.: PI, co-PI, conference and expertise fees from Amgen. The 101 participating physicians received a participation fee from APLUSA, based on a contract validated by the Conseil National de l’Ordre des Médecins (CNOM)."